Search Results

You are looking at 81 - 90 of 977 items for :

  • "quality of life" x
Clear All
Full access

William Breitbart and Yesne Alici

33 (36%) taking pemoline experienced clinically significant improvement, compared with 6 of 39 (15%) taking placebo. Improvement in fatigue was shown to correlate with improved quality of life, decreased depression, and decreased psychological

Full access

Brady L. Stein, Jason Gotlib, Murat Arcasoy, Marie Huong Nguyen, Neil Shah, Alison Moliterno, Catriona Jamieson, Daniel A. Pollyea, Bart Scott, Martha Wadleigh, Ross Levine, Rami Komrokji, Rebecca Klisovic, Krishna Gundabolu, Patricia Kropf, Meir Wetzler, Stephen T. Oh, Raul Ribeiro, Rita Paschal, Sanjay Mohan, Nikolai Podoltsev, Josef Prchal, Moshe Talpaz, David Snyder, Srdan Verstovsek and Ruben A. Mesa

meaningful improvements in quality of life and the MF symptom burden. Specifically, as assessed by a validated tool, a 50% or more improvement in baseline symptoms was seen in 45.9% of patients compared with 5.3% in the ruxolitinib versus placebo arm ( P

Full access

John A. Glaspy

The author has received research support from Amgen, Ortho Biotech, and Hoffman La Roche. References 1 Cella D Zagari MJ Vandoros C . Epoetin alfa treatment results in clinically significant improvements in quality of life in

Full access

Stephen G. Bown

needed to compare PDT with relevant comparators for all meaningful outcomes (effectiveness, safety, adverse events, quality of life, survival, and cost). In addition, quality studies from the patient perspective were necessary. If RCTs were not possible

Full access

Gwendolyn P. Quinn, Susan T. Vadaparampil, Clement K. Gwede, Joyce D. Reinecke, Tina M. Mason and Celso Silva

their cancer diagnosis. As higher rates of cancer survivorship are reached, the clinical focus has shifted from survival alone to include long-term quality-of-life issues. 2 One important quality-of-life issue in young patients is the potential

Full access

Claudia S.E.W. Schuurhuizen, Annemarie M.J. Braamse, Aartjan T.F. Beekman, Pim Cuijpers, Mecheline H.M. van der Linden, Adriaan W. Hoogendoorn, Hans Berkhof, Dirkje W. Sommeijer, Vera Lustig, Suzan Vrijaldenhoven, Haiko J. Bloemendal, Cees J. van Groeningen, Annette A. van Zweeden, Maurice J.D.L. van der Vorst, Ron Rietbroek, Cathrien S. Tromp-van Driel, Machteld N.W. Wymenga, Peter W. van der Linden, Aart Beeker, Marco B. Polee, Erdogan Batman, Maartje Los, Aart van Bochove, Jan A.C. Brakenhoff, Inge R.H.M. Konings, Henk M.W. Verheul and Joost Dekker

Background Cancer diagnosis and treatment are often associated with elevated levels of psychological distress, 1 , 2 which may cause poorer quality of life (QoL), reduced adherence to treatment, and potentially a poorer prognosis. 3 – 5 Routine

Full access

Ryan D. Nipp, Leah L. Thompson, Brandon Temel, Charn-Xin Fuh, Christine Server, Paul S. Kay, Sophia Landay, Daniel E. Lage, Lara Traeger, Erin Scott, Vicki A. Jackson, Nora K. Horick, Joseph A. Greer, Areej El-Jawahri and Jennifer S. Temel

literature as a tool that identifies older adults at risk for functional decline and death. 12 We prospectively collected patients’ self-reported quality of life (QoL), symptom burden, and functional impairments, and our primary objective was to compare

Full access

Jennifer A. Ligibel

diagnosis have lower rates of recurrence and death compared with sedentary individuals. A growing number of exercise intervention studies show that increased physical activity after diagnosis leads to improvements in quality of life, fatigue, and body image

Full access

Presenters : Mazyar Shadman and Deborah M. Stephens

improved quality of life “I will focus on ibrutinib, because it has the longest follow-up data of all these agents,” Dr. Stephens said. The first study she talked about was ECOG 1912, which was also discussed by Dr. Shadman. 2 ECOG 1912 randomized younger

Full access

Ronald C. Chen, William U. Shipley, Jason A. Efstathiou and Anthony L. Zietman

those who received neoadjuvant chemotherapy. Long-Term Morbidity, Bladder Function, and Quality of Life After Trimodality Therapy Approximately 75% to 80% of long-term survivors after trimodality therapy preserve their native bladders. 12 - 14